NEW YORK ( TheStreet) -- This new weekly column is intended to deliver actionable trade ideas using options for (mostly) small-cap biotech FDA drug approval and clinical trial catalysts. Where relevant, I will also focus on non-catalyst trade set-ups and other options-related topics in the biotech sector.
For those new to biotech investing, FDA drug approval and clinical trial catalysts cover a wide spectrum of major stock-moving events: Phase III clinical trial results, FDA drug approval announcements and FDA advisory committee meetings.
Small-cap biotech stocks are a high-risk asset class, which is why I like to use options when investing. Bad news -- whether it's poor data from an important clinical trial or FDA deciding to reject a new drug application -- can cause a biotech stock to plummet within minutes. Likewise, good news -- a successful clinical trial or an FDA drug approval -- can double the value of a biotech stock.
You get the point -- biotech investing is a high-risk, high-reward endeavor with binary outcomes. Trading or investing in just the equities exposes investors to a huge amount of risk and limits strategic choices. That is, investors can only buy, sell (if you already own) or short.Investing with options, on the other hand, increases the strategic choices available to an investor and can reduce risk while maintaining significant upside. I really believe that options are a perfect investment tool for the volatile biotech sector. I intend to use this column to show investors how to use options in biotech investing and each week, I'll discuss specific options trades. First, a quick sketch about my background and experience: I have more than 15 years as an options trader and currently trade options for my own account, exclusively focused on biotech catalysts. I'm the author of The Biotech Trader Handbook, co-founder of the biotech research and trading site Chimera Research Group and run an options trading web site, PelzOptions.com. Here's my first biotech options trading idea: Exelixis (EXEL - Get Report) is expecting to hear from FDA about a drug approval decision for its thyroid cancer drug cabozantinib by November 29. In early August, Exelixis announced a large equity and convertible bond offering that sent shares tumbling from over $6 to around $4.25. Last week, FDA notified Exelixis about the cancellation of a previously scheduled advisory panel for cabozantinib. That news caused Exelixis' shares to spike over $5 in after-hours trading but the stock quickly sold off to the low $4 the next day.